Search results
Results from the WOW.Com Content Network
Patients were randomly assigned to receive either 177 Lu-DOTATATE and octreotide LAR at a dose of 30 mg every four weeks for symptom control (n=116) or to only receive octreotide LAR at a dose of 60 mg every four weeks (n=113, control group). In total, 200 out of the 231 patients entered long-term follow-up.
Lanreotide, sold under the brand name Somatuline among others, is a medication used in the management of acromegaly and symptoms caused by neuroendocrine tumors, most notably carcinoid syndrome. It is a long-acting analogue of somatostatin , like octreotide .
In June 2020, octreotide (Mycapssa) was approved for medical use in the United States with an indication for the long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide. [13] [6] Mycapssa is the first oral somatostatin analog (SSA) approved by the FDA. [6]
An octreotide scan is a type of SPECT scintigraphy used to find carcinoid, pancreatic neuroendocrine tumors, and to localize sarcoidosis. It is also called somatostatin receptor scintigraphy (SRS). Octreotide , a drug similar to somatostatin , is radiolabeled with indium-111 , [ 1 ] and is injected into a vein and travels through the bloodstream.
Lanreotide (Somatuline, Ipsen Pharmaceuticals) is a medication used in the management of acromegaly and symptoms caused by neuroendocrine tumors, most notably carcinoid syndrome. It is a long-acting analog of somatostatin, like octreotide. It is available in several countries, including the United Kingdom, Australia, and Canada, and was ...
[11] [12] 68 Ga DOTA-TATE imagery has a much higher sensitivity and resolution compared to 111 In octreotide gamma camera or SPECT scans, due to intrinsic modality differences. [11] It is commonly used to confirm the presence of paragangliomas and pheochromocytomas.
The somatostatin hormone itself can negatively affect the uptake of hormones in the body and may play a role in some hormonal conditions. Somatostatin 2 receptors have been found in concentration on the surface of tumor cells, particularly those associated with the neuroendocrine system where the overexpression of somatostatin can lead to many complications [22] [23] Due to this, these ...
For patient eligibility to get Lutathera radioligand therapy the patient must have disease progression despite receiving somatostatin analog therapy (octreotide or lanreotide), have a locally advanced, inoperable, or metastatic well-differentiated disease, and have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.